Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With Metabolic Feedback for Dynamic Decision-Making

ConditionsProstate Cancer (Adenocarcinoma)Prostate Cancer (Diagnosis)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexMale

Age55+

SponsorShanghai Zhongshan Hospital

About this trial

Development of an Intelligent System Integrating Preoperative Imaging and Real-Time Intraoperative Metabolic Feedback to Dynamically Optimize Biopsy core Placement for Individualized Precision Sampling.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥55 years;

Indication for prostate biopsy;

Availability of total prostate-specific antigen (tPSA), free PSA (fPSA) levels, and multiparametric MRI (mpMRI) results within 1 month prior to biopsy.

Disqualifiers

Pathological diagnosis of malignancies other than prostatic acinar adenocarcinoma;

Concomitant malignant tumors potentially affecting imaging findings (e.g., rectal, bladder, or testicular cancer);

Cachexia or organ function decompensation.

Trial population

Patients who underwent prostate biopsy at three medical centers in Shanghai: Minhang Hospital, Fudan University; Xuhui Hospital, Fudan University and Shanghai Geriatric Medical Center

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

90 Participants

are grouped into 3 trial groups

Group A: Adaptive Biopsy Group

Group B: Systemic Biopsy Group

Group C: mpMRI Fusion Targeted Biopsy Group